Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study)
Public ClinicalTrials.gov record NCT05516498. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Two Part Phase IIa/b Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Dose-ranging Study to Assess Efficacy, Safety, and Tolerability of the Combination of Zibotentan and Dapagliflozin, and Dapagliflozin Monotherapy Versus Placebo in Participants With Cirrhosis With Features of Portal Hypertension
Study identification
- NCT ID
- NCT05516498
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- AstraZeneca
- Industry
- Enrollment
- 205 participants
Conditions and interventions
Conditions
Interventions
- Part A: Placebo (matching zibotentan capsule & matching dapagliflozin tablet) Drug
- Part A: zibotentan (dose B) + dapagliflozin Drug
- Part B: Placebo (matching zibotentan capsule & matching dapagliflozin tablet) Drug
- Part B: placebo (matching zibotentan capsule) + dapagliflozin Drug
- Part B: zibotentan (dose A) + dapagliflozin Drug
- Part B: zibotentan (dose B) + dapagliflozin Drug
- Part B: zibotentan (dose C) + dapagliflozin Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 30, 2022
- Primary completion
- May 21, 2025
- Completion
- Jul 16, 2025
- Last update posted
- Aug 14, 2025
2022 – 2025
United States locations
- U.S. sites
- 11
- U.S. states
- 8
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Birmingham | Alabama | 35233 | — |
| Research Site | Pasadena | California | 91105 | — |
| Research Site | San Francisco | California | 94115 | — |
| Research Site | West Hollywood | California | 90048 | — |
| Research Site | Rochester | Minnesota | 55905 | — |
| Research Site | The Bronx | New York | 10467 | — |
| Research Site | Charleston | South Carolina | 29425 | — |
| Research Site | Dallas | Texas | 75246 | — |
| Research Site | Charlottesville | Virginia | 22903 | — |
| Research Site | Richmond | Virginia | 23249 | — |
| Research Site | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 39 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05516498, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 14, 2025 · Synced May 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05516498 live on ClinicalTrials.gov.